The US Food and Drug Administration may need to consider accepting unvalidated patient-reported outcome measures in the context of very rare diseases, Center for Biologics Evaluation and Research Director Peter Marks said.
Unvalidated PROs In Rare Diseases: US FDA May Have To ‘Work Through’ Them, CBER’s Marks Says
Given the challenges of validating patient-reported outcome instruments specific to very rare diseases, agency is probably going to have to accept the use of unvalidated measures in some cases, Peter Marks tells American Society of Gene and Cell Therapy’s annual meeting.
